Detailed Brand Budgets in Pharmaceutical Marketing New Reports
Two new studies on pharmaceutical brand marketing show companies spending big dollars on potential blockbusters but pay attention to smaller niche drugs as well. The two Pharmaceutical Product Commercialization reports, "Pre-Clinical to Phase III Resource Allocation" and "Phase III to Post-Launch Resource Allocation," examine budget and staffing levels for 16 current drugs, both large and small. Findings include breakdowns of key spending categories and analyses of different brands' reactions to a range of competitive pressures. Business intelligence firm Cutting Edge Information will publish both studies in December 2004 and January 2005.
"Companies are spending their money very carefully," said Eric Bolesh, senior analyst at Cutting Edge Information. "No one's going to turn down a blockbuster, but we see much smaller drugs pulling in significant marketing budgets, too. Blockbuster or specialty product, these new brands will make winners out of smaller companies and will pull other firms through patents expirations."
The reports show how organizations such as Pfizer, Sanofi-Aventis, AstraZeneca, and Novartis fund their product launches. The reports feature more than 250 metrics that illustrate resource levels among brand teams working toward launch. Extensive metrics address the following areas: Marketing budget breakdowns from Pre-Clinical development through Post-Launch marketing, staffing resources for the same periods, brands' responses to competitive, clinical and internal challenges, key marketing activities and timelines and therapeutic area and brand team organizational structures.
Most read news
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.